Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.4.3 Market Structure
3 Research Methodology
3.1 Primary Research Methodology
3.2 Secondary Research Methodology
3.3 Market Size Estimation
3.4 Forecast Model
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising cases of breast cancer
4.2.2 Increasing rate of pregnancy
4.2.3 Unhygienic barn conditions causing contagious mastitis in bovines
4.3 Restraints
4.3.1 Lack of awareness
4.3.2 Complications in diagnosis due to similar symptoms of breast cancer & mastitis
4.4 Opportunity
4.4.1 Entering developing economies
4.5 Macroeconomics
4.5.1 Trends in Mastitis
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D & Designing
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Services
5.3 Investment Opportunities
5.4 Price Analysis
6 Global Mastitis Market, By Type
6.1 Introduction
6.2 Bovine
6.2.1 Contagious Mastitis
6.2.2 Environmental Mastitis
6.2.3 Opportunist Mastitis
6.3 Human
6.3.1 Non-Infectious Mastitis
6.3.2 Infectious Mastitis
7 Global Mastitis Market, By Treatment
7.1 Introduction
7.2 Bovine
7.2.1 Antibiotics
7.2.2 Vaccines
7.3 Human
7.3.1 Pain Relievers
7.3.2 Antibiotics
8 Global Mastitis Market, By End User
8.1 Introduction
8.2 Veterinary Centres
8.3 Hospital & Clinics
9 Global Mastitis Market, By Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 UK
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 Saudi Arabia
9.5.2 United Arab Emirates
9.5.3 Kuwait
9.5.4 Oman
9.5.5 Qatar
9.5.6 Rest of Middle East
10 Competitive Landscape
10.1 Competitive Scenario
10.1.1 Introduction
11 Company Profiles
11.1 Bayer AG
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products Offering
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategy
11.2 BioNumerik Pharmaceuticals Inc
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products/Services Offered
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategy
11.3 Oncothyreon Inc
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offered
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategy
11.4 Oncogenex
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offered
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategy
11.5 Apthera Inc.
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offered
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategy
11.6 Zoetis Inc
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products/Services Offered
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategy
11.7 Boehringer Ingelheim GmbH
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offered
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategy
11.8 Merck Co. & Inc
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products/Services Offered
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategy
11.9 Astellas Pharma Inc
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products/Services Offered
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategy
11.1 Pfizer Inc.
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products/Services Offered
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategy
11.11 Novartis AG
11.11.1 Company Overview
11.11.2 Financial Overview
11.11.3 Products/Services Offered
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.11.6 Key Strategy
11.12 Sanofi S.A.
11.12.1 Company Overview
11.12.2 Financial Overview
11.12.3 Products/Services Offered
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.12.6 Key Strategy
11.13 F. Hoffmann-La Roche AG
11.13.1 Company Overview
11.13.2 Financial Overview
11.13.3 Products/Services Offered
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.13.6 Key Strategy
12 Appendix
12.1 Discussion Blue Print
12.2 References